Production (Stage)
Silence Therapeutics plc
SLNCF
$1.59
$0.6263.92%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -375.94% | 129.41% | -79.05% | -749.11% | 86.77% |
| Total Depreciation and Amortization | -7.88% | 0.07% | -0.27% | -1.25% | 7.95% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 149.24% | -229.27% | 1,444.01% | -82.97% | -29.11% |
| Change in Net Operating Assets | 139.21% | -4,287.81% | -95.02% | 224.38% | -463.30% |
| Cash from Operations | 55.44% | -7.99% | -321.19% | 33.58% | 36.74% |
| Capital Expenditure | 93.92% | -3.13% | 24.50% | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -171.13% | 266.51% | -4,929.52% | 101.55% | -4,250.04% |
| Cash from Investing | -171.21% | 266.05% | -5,529.06% | 101.39% | -4,250.42% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | 473.06% | 49.48% | -- | -- |
| Issuance of Common Stock | -- | -- | 571.50% | -99.29% | 1,056.35% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 2,769.88% | -- | -- | -- |
| Cash from Financing | -99.00% | -82.01% | 626.83% | -99.20% | 961.50% |
| Foreign Exchange rate Adjustments | -96.45% | 200.34% | -3,228.18% | -458.57% | -107.03% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -232.43% | 168.91% | -1,271.82% | -106.10% | 2,974.68% |